IRADIMED CORPORATION Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Revenue $24.2 million, up 14% year over year in Q3 2026
- ➤GAAP diluted EPS $0.51, up 17% from Q3 2025
- ➤Q4 revenue guidance $25.0 million-$26.5 million targets a $100 million run rate
- ➤Full-year 2026 revenue guidance narrowed to $91.6 million-$93.1 million
- ➤Full-year GAAP diluted EPS guidance reduced to $1.90-$1.94 from $1.90-$2.05
Expert Statements
Roger Susi, President and Chief Executive Officer of Iradimed
“We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump. As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected. Quarterly bookings also set new records, driven by another record number of monitor units being booked and a 45% year-over-year increase in domestic pump channels booked. Of special note is that over 70% of pump bookings in the quarter were for our ‘quad stack’ configuration of four pumps on a single IV pole, as customers continue to accelerate their replacement of our older model and standardize on this setup which is a doubling of pump channels previously available at each MRI. With record bookings and rapidly building 3870 momentum, we believe we are well positioned for a strong finish to the year”
Roger Susi, President and Chief Executive Officer of Iradimed
“For the fourth quarter of 2026, we expect revenue of $25.0 million to $26.5 million, attaining a $100.0 million revenue run rate while generating GAAP diluted earnings per share of $0.53 to $0.57 and non-GAAP diluted earnings per share of $0.57 to $0.61. We revise our guidance for the full-year 2026, expecting to report revenue of $91.6 million to $93.1 million from $91.0 million to $96.0 million, and GAAP diluted earnings per share to $1.90 to $1.94 from $1.90 to $2.05 and non-GAAP diluted earnings per share to $2.07 to $2.11 from $2.06 to $2.21”
* Reports revenue of $24.2 million for the third quarter of 2026, which increased by $3.0 million, or 14% compared to the same period in 2025 and increased by $3.7 million or 18% compared to the second quarter of 2026. * Reports GAAP diluted EPS of $0.51 and non-GAAP diluted EPS of $0.55 for the third quarter of 2026 compared to GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.47 for the second quarter of 2026. * Declares a regular quarterly cash dividend of $0.20 per share of common stock for the third quarter of 2026, payable on November 27, 2026. ORLANDO, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2026. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) a non-magnetic patient vital signs monitoring system that are each designed for use during MRI procedures.
Get started
Create a free account to read the full story.